Liquidia Corporation is undergoing a significant digital transformation as it transitions from a development-focused biopharmaceutical company to a commercial entity. This involves enhancing systems and workflows across manufacturing, clinical operations, regulatory affairs, and commercialization to support the launch and growth of its product YUTREPIA. Their approach centers on leveraging advanced technological capabilities to optimize drug particle engineering and ensure stringent compliance in a regulated environment.
This transformation introduces critical dependencies on data accuracy and system integration, leading to potential operational challenges and risks. Specifically, failures in data management, process control, and regulatory submission workflows could impede product delivery and market access. This page will analyze key digital initiatives, pinpoint where breakdowns occur, and highlight opportunities for sellers to address these specific problems.
Liquidia Snapshot
Headquarters: Morrisville, NC
Number of employees: 201-500 employees
Public or private: Public
Business model: B2B
Website: https://www.liquidia.com
Liquidia ICP and Buying Roles
Liquidia sells to specialized healthcare providers and institutions focused on rare cardiopulmonary diseases. Their target market consists of high-complexity medical facilities and research centers requiring precise, innovative therapies.
Who drives buying decisions
- Chief Medical Officer → Oversees clinical strategy and patient outcomes
- Head of Commercial Operations → Manages product launch and market penetration
- Head of Regulatory Affairs → Ensures product compliance and submission integrity
- Head of Manufacturing → Controls production quality and facility operations
Key Digital Transformation Initiatives at Liquidia (At a Glance)
- Expanding YUTREPIA manufacturing production capacity.
- Centralizing clinical trial data management.
- Automating regulatory submission documentation.
- Integrating commercial sales and market access data.
- Optimizing PRINT® technology particle engineering.
Where Liquidia’s Digital Transformation Creates Sales Opportunities
| Vendor Type | Where to Sell (DT Initiative + Challenge) | Buyer / Owner | Solution Approach |
|---|---|---|---|
| Manufacturing Execution Systems | Expanding YUTREPIA manufacturing: production cleanroom equipment calibration records show inconsistencies. | Head of Manufacturing, Plant Operations Director | Standardize equipment calibration and maintenance records. |
| Expanding YUTREPIA manufacturing: raw material inventory levels display inaccuracies in enterprise resource planning. | Head of Supply Chain, Inventory Manager | Validate inventory data against physical counts. | |
| Expanding YUTREPIA manufacturing: batch release processes halt due to missing quality assurance documentation. | Head of Quality, Quality Control Manager | Enforce complete documentation before product release. | |
| Clinical Data Platforms | Centralizing clinical trial data: clinical data capture forms contain inconsistent patient information. | Head of Clinical Operations, Clinical Data Manager | Validate patient data entry against source documents. |
| Centralizing clinical trial data: study data discrepancies appear before database lock. | Clinical Data Manager, Head of Biostatistics | Detect and flag data inconsistencies automatically. | |
| Centralizing clinical trial data: medical information is not accurately coded for long-term storage. | Clinical Data Manager, Regulatory Affairs Lead | Standardize medical data coding and retention policies. | |
| Regulatory Information Management | Automating regulatory submission: regulatory document versions do not align across departments. | Director of Global Regulatory Affairs, Head of Regulatory Operations | Validate document version control across all platforms. |
| Automating regulatory submission: submission dossiers contain outdated chemistry, manufacturing, and controls sections. | Head of Regulatory Affairs, CMC Lead | Update outdated sections before submission. | |
| Automating regulatory submission: health authority information requests receive delayed responses. | Regulatory Affairs Manager | Route information requests to appropriate teams. | |
| Commercial Operations Platforms | Integrating commercial sales data: sales forecasts do not synchronize with product inventory levels. | Senior Vice President of Marketing, Commercial Operations Lead | Validate sales projections against available stock. |
| Integrating commercial sales data: market access data contains inconsistent payer policy information. | Senior Vice President of Market Access | Enforce data consistency for payer policy records. | |
| Integrating commercial sales data: customer relationship management entries lack complete prescriber details. | Commercial Operations Lead, Sales Director | Standardize prescriber data input protocols. | |
| Process Analytical Technology | Optimizing PRINT® technology: particle size distribution measurements drift outside defined parameters. | Head of R&D, Director of Process Development | Detect deviations from target particle characteristics. |
| Optimizing PRINT® technology: process analytical technology data streams show intermittent connectivity with control systems. | Director of Process Development, Process Engineer | Validate data stream connectivity between instruments. | |
| Optimizing PRINT® technology: manufacturing parameters for particle characteristics display inconsistencies across batches. | Head of R&D, Quality Control Manager | Enforce consistent manufacturing parameter settings. |
Identify when companies like Liquidia are in-market for your solutions.
Spot buying signals, find the right prospects, enrich your data, and reach out with relevant messaging at the right time.
What makes this Liquidia’s digital transformation unique
Liquidia's digital transformation heavily depends on the precise application and scaling of its proprietary PRINT® technology. This requires specialized systems for particle engineering and stringent quality control, differentiating their needs from typical biopharma companies. Their transformation is uniquely complex due to the intricate regulatory landscape surrounding advanced drug delivery mechanisms and the rapid commercialization of their core product, YUTREPIA. They prioritize integrated data visibility across highly specialized R&D, manufacturing, and regulatory workflows.
Liquidia’s Digital Transformation: Operational Breakdown
DT Initiative 1: Expanding YUTREPIA manufacturing production capacity
What the company is doing
Liquidia is leasing a significant new facility to add production cleanroom space for YUTREPIA. This initiative supports increased commercial supply needs and accommodates future product manufacturing requirements. The expansion includes new manufacturing lines and dedicated analytical labs.
Who owns this
- Senior Vice President of Manufacturing Operations
- Head of Quality
- Plant Operations Director
Where It Fails
- Manufacturing execution system data does not integrate with quality control labs.
- Production cleanroom equipment calibration records show inconsistencies.
- Raw material inventory levels display inaccuracies in enterprise resource planning.
- Batch release processes halt due to missing quality assurance documentation.
Talk track
Noticed Liquidia is expanding manufacturing capacity for YUTREPIA. Been looking at how other biopharma companies are standardizing equipment data streams to prevent production delays, can share what’s working if useful.
DT Initiative 2: Centralizing clinical trial data management
What the company is doing
Liquidia conducts multiple clinical trials for YUTREPIA and investigational products like L606, generating extensive patient and study data. This involves collecting and managing diverse medical information from various procedures and assessments.
Who owns this
- Head of Clinical Operations
- Clinical Data Manager
- Head of Biostatistics
Where It Fails
- Clinical data capture forms contain inconsistent patient information.
- Study data discrepancies appear before database lock.
- Medical information is not accurately coded for long-term storage.
- Audit trails for data changes lack complete user attribution.
Talk track
Seems like Liquidia manages extensive clinical trial data for ongoing studies. Been looking at how some research teams are validating patient data entry upfront to prevent downstream reconciliation issues, happy to share what we’re seeing.
DT Initiative 3: Automating regulatory submission documentation
What the company is doing
Liquidia prepares and submits New Drug Applications and amendments to the FDA for its products like YUTREPIA. This requires managing and compiling comprehensive documentation, including detailed chemistry, manufacturing, and controls sections.
Who owns this
- Director of Global Regulatory Affairs
- Head of Regulatory Operations
- VP of Quality and Compliance
Where It Fails
- Regulatory document versions do not align across departments.
- Submission dossiers contain outdated chemistry, manufacturing, and controls sections.
- Health authority information requests receive delayed responses.
- Device quality system records show gaps against ISO 13485 standards.
Talk track
Looks like Liquidia handles complex regulatory submissions for new drug approvals. Been seeing how some regulatory teams are enforcing document version control across all systems to avoid submission errors, can share what’s working if useful.
DT Initiative 4: Integrating commercial sales and market access data
What the company is doing
Liquidia is expanding its sales force and commercial strategies for YUTREPIA's market launch and penetration. This effort demands seamless integration of market access data, sales figures, and financial information for effective commercial execution.
Who owns this
- Senior Vice President of Market Access
- Senior Vice President of Marketing
- Chief Commercial Officer
Where It Fails
- Sales forecasts do not synchronize with product inventory levels.
- Market access data contains inconsistent payer policy information.
- Commercial spending reports show miscategorized expense entries.
- Customer relationship management entries lack complete prescriber details.
Talk track
Noticed Liquidia is expanding commercial operations for YUTREPIA. Been looking at how some commercial teams are validating market access data consistency to prevent revenue leakage, happy to share what we’re seeing.
DT Initiative 5: Optimizing PRINT® technology particle engineering
What the company is doing
Liquidia leverages its proprietary PRINT® technology to design and manufacture precise drug particles for therapeutic applications. This core activity requires continuous refinement of engineering processes and controls to maintain specific particle characteristics.
Who owns this
- Head of R&D
- Director of Process Development
- Chief Scientific Officer
Where It Fails
- Particle size distribution measurements drift outside defined parameters.
- Process analytical technology data streams show intermittent connectivity with control systems.
- Formulation development records lack complete historical experimental data.
- Manufacturing parameters for particle characteristics display inconsistencies across batches.
Talk track
Saw Liquidia focuses on precise particle engineering with its PRINT® technology. Been looking at how some R&D teams are detecting deviations in particle characteristics automatically to ensure product quality, can share what’s working if useful.
Who Should Target Liquidia Right Now
This account is relevant for:
- Manufacturing quality management system providers
- Clinical data management and analytics platforms
- Regulatory information management software vendors
- Commercial operations and sales performance management solutions
- Process analytical technology and manufacturing intelligence tools
Not a fit for:
- Basic website builders with no integration capabilities
- Standalone marketing tools without system connectivity
- Products designed for small, low-complexity teams
When Liquidia Is Worth Prioritizing
Prioritize if:
- You sell solutions for standardizing equipment calibration and maintenance records in GMP environments.
- You sell clinical data validation tools that detect and flag inconsistencies before database lock.
- You sell regulatory content management platforms that enforce document version control across departments.
- You sell commercial operations platforms that synchronize sales forecasts with real-time inventory levels.
- You sell process analytical technology solutions that detect deviations in particle characteristics during manufacturing.
Deprioritize if:
- Your solution does not address any of the breakdowns above.
- Your product is limited to basic functionality with no integration capabilities for biopharma systems.
- Your offering is not built for multi-team or multi-system environments within a regulated industry.
Who Can Sell to Liquidia Right Now
Manufacturing Quality Management Systems
MasterControl - This company offers a quality management system specifically designed for life sciences companies to ensure compliance and manage quality processes.
Why they are relevant: Liquidia's manufacturing expansion requires strict adherence to quality and compliance standards. MasterControl can standardize equipment calibration records and enforce complete documentation for batch release processes, preventing halts in production.
ComplianceQuest - This company provides a cloud-based quality and compliance management software built on the Salesforce platform.
Why they are relevant: Liquidia needs robust systems to manage its expanded manufacturing operations. ComplianceQuest can help manage equipment calibration inconsistencies and ensure all quality assurance documentation is complete and accessible, streamlining batch releases.
Clinical Data Management and Analytics Platforms
Medidata Solutions - This company offers a comprehensive platform for clinical trial data management, analytics, and electronic data capture.
Why they are relevant: Liquidia's ongoing clinical trials generate vast amounts of data that require accurate management. Medidata can validate patient data entry and detect study data discrepancies early, preventing data issues before database lock.
Veeva Systems - This company provides cloud-based software for the global life sciences industry, including clinical data management.
Why they are relevant: Liquidia needs to centralize and accurately manage clinical trial data. Veeva can standardize medical information coding for long-term storage and ensure complete audit trails for data changes, maintaining data integrity and compliance.
Regulatory Information Management Software
IQVIA (SmartSolve®) - This company offers an integrated software solution that consolidates quality and regulatory management responsibilities into a single platform.
Why they are relevant: Liquidia faces continuous regulatory scrutiny and needs to manage complex submissions. SmartSolve can enforce document version control across departments and ensure submission dossiers contain up-to-date information, speeding up responses to health authority requests.
ArisGlobal - This company provides life sciences software platforms for drug development and regulatory affairs, including regulatory information management.
Why they are relevant: Liquidia's regulatory submissions require precise document management and timely responses. ArisGlobal can standardize regulatory document workflows and route information requests efficiently, preventing delays caused by outdated or inconsistent content.
Commercial Operations and Sales Performance Management
Veeva Commercial Cloud - This company offers a suite of cloud applications designed for commercial functions in the life sciences industry, including CRM and sales.
Why they are relevant: Liquidia's sales force expansion and commercialization of YUTREPIA require integrated data. Veeva Commercial Cloud can synchronize sales forecasts with product inventory levels and enforce consistent data entry for prescriber details in CRM systems, preventing discrepancies.
Symphony Health (now part of ICON) - This company provides data, analytics, and technology solutions for pharmaceutical commercial operations.
Why they are relevant: Liquidia needs to effectively manage its market access and commercial spending. Symphony Health solutions can help validate market access data for consistent payer policy information and accurately categorize commercial spending reports, improving financial visibility.
Process Analytical Technology and Manufacturing Intelligence
Dassault Systèmes (DELMIA) - This company provides quality management systems tailored for industries requiring precision and compliance, integrating with MES and ERP.
Why they are relevant: Liquidia's PRINT® technology requires precise process control and data integrity. DELMIA can detect deviations in particle size distribution measurements and validate data stream connectivity from process analytical technology with control systems, ensuring consistent product quality.
Thermo Fisher Scientific (SampleManager LIMS) - This company offers Laboratory Information Management Systems (LIMS) crucial for managing analytical data in R&D and manufacturing.
Why they are relevant: Liquidia's PRINT® technology relies on detailed formulation development and manufacturing data. SampleManager LIMS can manage formulation development records and ensure consistent manufacturing parameters for particle characteristics across batches, preventing inconsistencies.
Final Take
Liquidia is actively scaling its manufacturing operations and commercial infrastructure while managing complex clinical development and regulatory processes. Breakdowns are visible in data synchronization across systems, document version control, and real-time operational visibility within highly specialized workflows. This account is a strong fit for solutions that prevent inconsistencies in manufacturing, standardize data in clinical trials, enforce regulatory document integrity, and integrate commercial and supply chain planning.
Identify buying signals from digital transformation at your target companies and find those already in-market.
Find the right contacts and use tailored messages to reach out with context.